| Old Articles: <Older 4831-4840 Newer> |
|---|
 |
Chemistry World
May 8, 2008
Hepeng Jia |
China to fast track pioneering drugs China is to speed up the approval of groundbreaking new drugs in an effort to encourage innovation in its pharmaceutical sector, a State Food and Drug Administration (SFDA) official has revealed.   |
The Motley Fool
May 7, 2008
Brian Orelli |
Black Onyx, but Not for Long Onyx posts a stellar quarter, but earnings for the pharmaceuticals company are headed in the other direction for the rest of the year. |
The Motley Fool
May 7, 2008
Brian Orelli |
Teva's on a Tear The generic-drug maker can't be stopped. |
The Motley Fool
May 7, 2008
Brian Lawler |
Cephalon's Long Shot Falls Short An FDA advisory panel brings bad news for the company. |
The Motley Fool
May 6, 2008
Brian Orelli |
A Sign of the Pharma Times Merck is the latest big pharma cutting jobs to improve its bottom line. |
The Motley Fool
May 6, 2008
Brian Lawler |
MannKind Moves Ahead The pharmaceutical awaits pivotal data on its lead drug Technosphere. |
The Motley Fool
May 6, 2008
Steven Renaldi |
McKesson Garners Generic Growth New products offer the generic-drug distributor profit potential in a competitive industry. |
Information Today
May 5, 2008 |
Premerus Introduces Medical Misdiagnosis Portal Premerus provides a platform for consumers to read and post their own experiences to share insights about the impact of diagnostic errors. |
The Motley Fool
May 5, 2008
Brian Orelli |
A Short Wait for Discovery Labs? The company gets a third letter about Surfaxin, but should be able to satisfy the FDA soon. |
The Motley Fool
May 5, 2008
Brian Lawler |
Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week. |
| <Older 4831-4840 Newer> Return to current articles. |
